Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $655 to $570.
Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $570
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.